Neuronetics, Inc. Files 8-K for Financial Reporting

Ticker: STIM · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1227636

Neuronetics, Inc. 8-K Filing Summary
FieldDetail
CompanyNeuronetics, Inc. (STIM)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages5
Reading Time5 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting

TL;DR

Neuronetics filed an 8-K on Jan 13, 2025, for financial reporting. No specific numbers yet.

AI Summary

Neuronetics, Inc. filed an 8-K on January 13, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits. The filing does not contain specific financial figures or operational updates within the provided text, but indicates a standard reporting event.

Why It Matters

This filing signals that Neuronetics is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor the company's performance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial reporting and does not contain any immediately alarming information.

Key Players & Entities

  • Neuronetics, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Malvern, PA (location) — Principal Executive Offices

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided text of the 8-K filing indicates it covers 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Financial Statements and Exhibits,' but does not include specific financial figures or operational details within the excerpt.

When was this 8-K report filed with the SEC?

This 8-K report was filed on January 13, 2025.

What is the principal business address of Neuronetics, Inc.?

The principal executive offices of Neuronetics, Inc. are located at 3222 Phoenixville Pike, Malvern, PA 19355.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

What is the SIC code for Neuronetics, Inc.?

The Standard Industrial Classification (SIC) code for Neuronetics, Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.

Filing Stats: 1,369 words · 5 min read · ~5 pages · Grade level 14.1 · Accepted 2025-01-13 08:04:32

Key Financial Figures

  • $0.01 — ange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M

Filing Documents

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 NEURONETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38546 33-1051425 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3222 Phoenixville Pike , Malvern , PA 19355 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (610) 640-4202 (Former name or former address, if changed since last report.) Not applicable. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name on each exchange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item2.02 Results of Operations and Financial Condition. Neuronetics, Inc., or the Company, issued a press release on January 13, 2025, announcing certain preliminary financial information for the three and twelve months ended December 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. *** The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished. Item7.01 Regulation FD Disclosure. On January 13, 2025, Neuronetics released a presentation (the "Presentation") that it may present to certain investors. A copy of the Presentation in connection therewith is attached hereto as Exhibit 99.2. The information contained in Exhibit 99.2 is incorporated herein by reference. The information in this report furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished. "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this Current Report, including the documents incorporated by reference herein, include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and "forward-looking information" within the meaning of applicable Canadian securities laws. Statements in this Current Report that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Ac

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.